Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial

Journal of Allergy and Clinical Immunology

Volumn 134, Issue 3, 2014, Pages

  Mosbech, Holger ^a   Deckelmann, Regina ^b   De Blay, Fréderic ^c   Pastorello, Elide Anna ^d   Trebas Pietras, Ewa ^e   Andres, Luis Prieto ^f   Malcus, Inga ^e   Ljørring, Christian ^g   Canonica, Giorgio Walter ^h  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b SALVUS UG Centre for Clinical Trials   (Germany)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e Valencia University ^*

^f UNIVERSITY OF VALENCIA   (Spain)

^g ALK ABELLÓ   (Denmark)

^h UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergy; allergy immunotherapy; asthma; asthma control; house dust mite; immunotherapy; inhaled corticosteroid; respiratory allergic disease; SLIT tablet; SQ

Indexed keywords

BUDESONIDE; CORTICOSTEROID; HOUSE DUST ALLERGEN; PLACEBO; TABLET;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CONTROLLED STUDY; DEPRESSION; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FACE EDEMA; FATIGUE; FORCED EXPIRATORY VOLUME; HOUSE DUST ALLERGY; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; METERED DOSE INHALER; MIGRAINE; MUCOSAL EDEMA; MYALGIA; OUTCOME ASSESSMENT; PARESTHESIA; PEAK EXPIRATORY FLOW; PHARYNX DISEASE; PHARYNX EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STANDARDIZATION; STOMATITIS; SUBLINGUAL IMMUNOTHERAPY; TABLET; THORAX PAIN; TONGUE SWELLING; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; CLINICAL PRACTICE; DESENSITIZATION; DISEASE COURSE; DOSE CALCULATION; FEMALE; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; MALE; PROCEDURES; PYROGLYPHIDAE; QUALITY CONTROL; STANDARD; STANDARDS; STATISTICS AND NUMERICAL DATA; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PYROGLYPHIDAE; QUALITY CONTROL; REFERENCE STANDARDS; TABLETS; TREATMENT OUTCOME;

EID: 84906944915     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2014.03.019     Document Type: Article

References (47)

1. V. Bauchau, and S.R. Durham Prevalence and rate of diagnosis of allergic rhinitis in Europe Eur Respir J 24 2004 758 764
2. M. Masoli, D. Fabian, S. Holt, and R. Beasley Global burden of asthma Allergy 59 2004 469 478
3. T.B. Knudsen, S.F. Thomsen, H. Nolte, and V. Backer A population-based clinical study of allergic and non-allergic asthma J Asthma 46 2009 91 94
4. M. Zureik, C. Neukirch, B. Leynaert, R. Liard, J. Bousquet, and F. Neukirch Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey BMJ 325 2002 411 414
5. A. Linneberg, N. Henrik Nielsen, L. Frolund, F. Madsen, A. Dirksen, and T. Jorgensen The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study Allergy 57 2002 1048 1052
6. J. Bousquet, R.F. Lockey, and H.J. Malling WHO Position Paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases Allergy 53 1998 1 42
7. J. Bousquet, N. Khaltaev, A.A. Cruz, J. Denburg, W.J. Fokkens, and A. Togias et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy 63 Suppl 86 2008 8 160
8. S.R. Durham, S.M. Walker, E.M. Varga, M.R. Jacobson, F. O'Brien, and W. Noble et al. Long-term clinical efficacy of grass-pollen immunotherapy N Engl J Med 341 1999 468 475
9. M. Marogna, I. Spadolini, A. Massolo, G.W. Canonica, and G. Passalacqua Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study J Allergy Clin Immunol 126 2010 969 975
10. L. Jacobsen, B. Niggemann, S. Dreborg, H.A. Ferdousi, S. Halken, and A. Host et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study Allergy 62 2007 943 948
11. S.R. Durham, W. Emminger, A. Kapp, J.G.R. de Monchy, S. Rak, and G.K. Scadding et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial J Allergy Clin Immunol 129 2012 717 725
12. J.L. Brozek, J. Bousquet, C.E. Baena-Cagnani, S. Bonini, G.W. Canonica, and T.B. Casale et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision J Allergy Clin Immunol 126 2010 466 476
13. G.W. Canonica, J. Bousquet, T. Casale, R.F. Lockey, C.E. Baena-Cagnani, and R. Pawankar et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009 WAO J 2 2009 233 281
14. GINA Executive Committee Global Initiative for Asthma; global strategy for asthma management and prevention 2011 National Heart, Lung and Blood Institute, National Institute of Health Bethesda (MD)
15. ICH. ICH Harmonised tripartite guideline topic e8: general considerations for clinical trials. 1997.
16. E.F. Juniper, J. Bousquet, L. Abetz, and E.D. Bateman Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire Respir Med 100 2006 616 621
17. ICH. ICH harmonised tripartite guideline topic e6 (r1): guideline for good clinical practice. 1996.
18. J.L. Corzo, T. Carrillo, C. Pedemonte, A.M.P. Martin, S.M. Hurtado, and E. Dige et al. Tolerability during double-blinded randomised phase I trials with the house dust mite allergy immunotherapy tablet in adults and children J Investig Allergol Clin Immunol 2014 [in press]
19. From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Available at: http://www.ginaasthma.org/.
20. E.F. Juniper, G.H. Guyatt, R.S. Epstein, P.J. Ferrie, R. Jaeschke, and T.K. Hiller Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials Thorax 47 1992 76 83
21. E.F. Juniper, P.M. O'Byrne, P.J. Ferrie, D.R. King, and J.N. Roberts Measuring asthma control Am J Respir Crit Care Med 162 2000 1330 1334
22. ICH. ICH harmonised tripartite guideline topic e9: statistical principles for clinical trials. 1998.
23. R. Dahl, A. Kapp, G. Colombo, J.G. De Monchy, S. Rak, and W. Emminger et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years J Allergy Clin Immunol 121 2008 512 518
24. R. Dahl, A. Kapp, G. Colombo, J. de Monchy, S. Rak, and W. Emminger et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis J Allergy Clin Immunol 118 2006 434 440
25. R. Dahl, A. Stender, and S. Rak Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis Allergy 61 2006 185 190
26. A. Bufe, P. Eberle, E. Franke-Beckmann, J. Funck, M. Kimmig, and L. Klimek et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy J Allergy Clin Immunol 123 2009 167 173
27. M. Blaiss, J. Maloney, H. Nolte, S. Gawchik, R. Yao, and D.P. Skoner Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents J Allergy Clin Immunol 127 2011 64 71
28. H.S. Nelson, H. Nolte, P. Creticos, J. Maloney, J. Wu, and D.I. Bernstein Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults J Allergy Clin Immunol 127 2011 72 80
29. A. Didier, M. Worm, F. Horak, G. Sussman, B.O. de, and G.M. Le et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis J Allergy Clin Immunol 128 2011 559 566
30. H.J. Malling, A. Montagut, M. Melac, G. Patriarca, P. Panzner, and E. Seberova et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis Clin Exp Allergy 39 2009 387 393
31. A. Didier, H. Malling, M. Worm, F. Horak, S. Jäger, and A. Montagut et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis J Allergy Clin Immunol 120 2007 1338 1345
32. U. Wahn, A. Tabar, P. Kuna, S. Halken, A. Montagut, and O. de Beaumont et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis J Allergy Clin Immunol 123 2009 160 166
33. S.R. Durham, W. Emminger, A. Kapp, G. Colombo, J.G. De Monchy, and S. Rak et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet J Allergy Clin Immunol 125 2010 131 138
34. M.D. Ibanez, F. Kaiser, R. Knecht, A. Armentia, H. Schopfer, and B. Tholstrup et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children Pediatr Allergy Immunol 18 2007 516 522
35. F. Kette, and W. Smith Sublingual immunotherapy: allergen specific or placebo effect? J Allergy Clin Immunol 128 2011 430 432
36. M. Blaiss, H.S. Nelson, S.R. Durham, R. Dahl, and A. Bufe Reply to Kette and Smith: sublingual immunotherapy: allergen specific or placebo effect? J Allergy Clin Immunol 128 2011 430 432
37. G. Blumberga, L. Groes, L. Haugaard, and R. Dahl Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics Allergy 61 2006 843 848
38. S. Walker, M. Monteil, K. Phelan, T.J. Lasserson, and E.H. Walters Anti-IgE for chronic asthma in adults and children Cochrane Database Syst Rev 2 2006 CD003559
39. S. Zielen, P. Kardos, and E. Madonini Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial J Allergy Clin Immunol 126 2010 942 949
40. M.A. Calderon, L. Cox, T.B. Casale, P. Moingeon, and P. Demoly Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence J Allergy Clin Immunol 129 2012 929 934
41. G. Ciprandi, S. Buscaglia, G. Pesce, C. Pronzato, V. Ricca, and S. Parmiani et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy J Allergy Clin Immunol 96 1995 971 979
42. H.K. Reddel, D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, and W.W. Busse et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice Am J Respir Crit Care Med 180 2009 59 99
43. G. Blumberga, L. Groes, L. Haugaard, and R. Dahl Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics Allergy 61 2006 843 848
44. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children (Cochrane Review). The Cochrane Library [1]. Chichester, UK, John Wiley & Sons, Ltd; 2006.
45. National Institutes of health. WHO/GINA workshop report: Global Strategy for asthma management and prevention. NIH publication No 02-3659, 1-192; 2002.
46. European community for coal and steel. Standardisation of lung function tests. Bull Europ Physiopath Resp 1983;19(suppl 5).
47. From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). Available at: http://www.ginaasthma.org/. 2010.